

DAFTAR PUSTAKA

- Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. 2007. *Peritoneal Natural Killer Cells from Epithelial Ovarian Cancer patient Show an Altered Phenotype and Bind to the Tumor Marker MUC16 (CA125)*, Immunology, Blackwell Publishing Ltd.
- Bessoles et al.2014. *Adaptations of Natural Killer Cells to Self-MHC Class I*, Frontiers in Immunology, volume 5, July 2014
- Budiana,I.N. 2013. Tumor Ovarium: Prediksi Keganasan Prabedah. *Jurnal Ilmiah Kedokteran* , 44 (Divisi Onkologi- Ginekologi, Departemen Obstetri dan Ginekologi FK Unud/RSUP Sanglah Denpasar), 179-85.
- Cannistra, S.A., Gershenson, D.M., Recht, A. 2011.*Ovarian Cancer, Fallopian Tube Carcinoma, And Peritoneal Carcinoma*.DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology 9th. LIPPINCOTT WILLIAMS & WILKINS. 1368-1389.
- Comamala M, Pinard M, Theriault C. 2011. *Downregulation Of Cell Surface CA125/MUC16 Induces Epithelial-To-Mesenchymal Transition And Restores EGFR Signalling In NIH:OVCAR3 Ovarian Carcinoma Cells*. British Journal of Cancer (2011) 104, 989 – 999
- Daniel W. Chan, et al. 2009. *Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers*. Washington, United State: the American Association for Clinical Chemistry, Inc.
- Di Santo JP. 2008. *Natural Killer Cells: Diversity in Search of a Niche*, Nature Immunology, volume 9, number 5.
- Estrella ML, et al. 2011. *Natural Killer Cell in Human Cancer: From Biological Function to Clinical Applications*, Journal of Biomed and Technology, Hindawi Publishing Corporation.
- Farid Aziz dkk. 2006. *Onkologi Ginekologi* edisi pertama; Yayasan Bina Pustaka Sarwono Prawiroharjo, Jakarta ; 469 – 527.
- Garret Ap. Berkowitz RR. 2003. *Natural History and Detection of Ovarian Carcinoma*, Sciarra, Gynecologic and Obstetrics, Philadelphia: Lippincott-Raven Publisher, 2003. Chapter 28 Vol 4,Page 1-13.
- Goff BA, Mandel LS, Melancon CH, Muntz HG. 2004. *Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics* in Journal of American Medical Assosiation vol 291 no 22.

- Gubbels, et al. 2010. *MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells*, *BioMed central, Molecular Cancer*.
- Hariadi TS, Siregar HS, Tala MR, Lubis R, Rivany R, Aldiansyah D.2015. *Ekspresi Imunohistokimia Aktivitas Sel Natural Killer Dengan Cd107a Pada Endometrium Ektopik Penderita Endometriosis Dibandingkan Dengan Endometrium Normal*. Universitas Sumatera Utara.
- Haridas D, Ponnusamy MP, Chugh S. 2014. *MUC16: Molecular Analysis And Its Functional Implications In Benign And Malignant Conditions*. The FASEB Journal. Vol. 28:4183-99.
- Hillary SW, Mark JS. 1999. *NK Cells and Apoptosis*, Immunology and Cell Biology.
- Jelovac D, Armstrong DK. 2011. *Recent Progress in the Diagnosis and Treatment of Ovarian Cancer* CA Cancer J Clin. American Cancer Society.
- Lalwani N., Prasad S.R., Vikram R., et al. 2011. *Histologic, Molecular, and Cytogenetic Features of Ovarian Cancers: Implications for Diagnosis and Treatment*. RadioGraphics 2011; 31:625–646.
- Markasz L et al. 2007. *Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells*, *Molecular Cancer Therapeutic* vol 7, page 644-654.
- Mannish S et al. 2005. *Potent Supression of Natural Cel Killer Response Mediated by the Ovarian Tumor Marker CA125*, science direct.
- Muccioli M et al. 2014. *Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies*, *Frontiers of immunology*, volume 5, article 341.
- Moore RG, et al. 2012. *Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders*. *American Journal of Obstetrics & Gynecology* , 351.e1.
- National Collaborating Centre for Cancer. 2011. *Ovarian cancer: the recognition and initial management of ovarian cancer*, Evidence review, NICE.
- Olson H. 2001. *Symptoms of Ovarian Cancer*, *Obstet Gynecol*; 98: 212-17.

- Orsulic S, 2009. *Ovarian Cancer* downloaded from <http://www.cedars-sinai.edu/Research-and-Education/Research-Labs/Orsulic-Lab/Documents/PDF-1.pdf> on August 12th 2014.
- Piver MS. 2003. *Epidemiologic Perspective of Ovarian Cancer*, Sciarra, Gynecologic and Obstetrics, Philadelphia: Lippincott-Raven Publisher, 2003. Chapter 27 Vol 4, Page 1-10.
- Prasetyo, EY. 2015. *Lysophosphatidic Acid dan Cancer Antigen 125 pada Kanker Ovarium*. Universitas Hasanudin, Makasar.
- Rahardjo, TAB., Tjokroprawiro BA. 2014. *Akurasi Kadar Lysophosphatidic Acid Plasma dan CA125 Serum Penderita Tumor Ovarium Jenis Epitel untuk Prediktor Keganasan Ovarium*. Indonesian Journal of Cancer Vol. 8, No. 2. 51-61
- Rarung, M. 2008. *Sensitifitas dan Spesifisitas Petanda Tumor CA125 sebagai Prediksi Keganasan Ovarium*. *JKM*, 9-14.
- Rein BJD, Gupta s, Dada R, et al. 2011. *Potential Markers for Detection and Monitoring of Ovarian Cancer*. Hindawi Publishing Corporation Journal of Oncology. Volume 2011:1-1
- Roett, MA; Evans P. 2009. *Ovarian Cancer: An Overview* in September 15, Volume 80, Number 6 www.aafp.org/afp American Family Physician.
- Romee R et al. 2014. *Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer*, Scientifica, Hindawi Publishing Corporation.
- Sihombing M & Sirait A. 2007. *Angka Ketahanan Hidup Penderita Kanker Ovarium di RS Dr. Cipto Mangunkusumo Jakarta*. Pusat Penelitian dan Pengembangan Biomedis dan Farmasi, Badan Penelitian dan Pengembangan Kesehatan RI.
- Thériault C, Pinard M, Comamala M, et al. 2011. *MUC16 (CA125) Regulates Epithelial Ovarian Cancer Cell Growth, Tumorigenesis And Metastasis*. *Gynecologic Oncology* 121, 434–443.
- Vivier E, et al. 2008. *Functions of natural killer cells*, *Nature Immunology*, Volume 9, Number 5.
- Vivier E, et al. 2012. *Targetting Natural Killer Cells and Natural Killer T Cells in Cancer*, *Immunology*, Macmillan Publisher Ltd, 2012
- Zoya Yurkovetsky, et al. 2010. *Development of a Multimarker Assay for Early Detection of Ovarian Cancer*. *Journal Of Clinical Oncology* ,28 (University of Pittsburgh), 2159-66.